Related Experiment Video

Updated: Aug 9, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Cost-effectiveness considerations in the treatment of heterozygous familial hypercholesterolemia with medications

L Goldman1, P A Goldman, L W Williams

  • 1Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115.

The American Journal of Cardiology
|September 30, 1993
PubMed

Insights

Hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors effectively prevent coronary heart disease in heterozygous familial hypercholesterolemia (hFH) patients. Low-to-moderate doses offer favorable cost-effectiveness, supporting their use in primary prevention strategies.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacoeconomics
  • Genetics

Background:

  • Heterozygous familial hypercholesterolemia (hFH) significantly increases coronary heart disease (CHD) risk.
  • Primary prevention of CHD in hFH patients is crucial for long-term health outcomes.
  • Cost-effectiveness of lipid-lowering therapies in hFH requires careful evaluation.

Purpose of the Study:

  • To evaluate the cost-effectiveness of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors for primary CHD prevention in hFH.
  • To determine optimal dosing strategies for HMG CoA reductase inhibitors in hFH patients.
  • To compare the cost-effectiveness of hFH primary prevention with other cardiovascular prevention strategies.

Main Methods:

  • Pharmacoeconomic modeling was used to project costs and outcomes.
  • Analysis included various doses of HMG CoA reductase inhibitors (e.g., lovastatin).
  • Cost-effectiveness ratios were calculated per year of life saved.

Main Results:

  • Low-to-medium doses of HMG CoA reductase inhibitors demonstrated favorable cost-effectiveness for primary CHD prevention in hFH.
  • 20 mg of lovastatin daily was cost-effective for men and women (with risk factors) aged 35-44.
  • Higher doses (40-80 mg) showed significantly increased costs per year of life saved.

Conclusions:

  • HMG CoA reductase inhibitors, particularly at low-to-moderate doses, are cost-effective for primary CHD prevention in hFH.
  • Cost considerations should be integrated into national recommendations for hFH treatment.
  • Low-to-moderate dose statin therapy is supported for primary prevention in hFH patients.

More Related Videos

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...